In Deals With Respivert And Orexo, J&J's Respiratory Push Gets Going

J&J acquired respiratory drug discovery firm Respivert and licensed two respiratory preclinical research programs from Orexo.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet